MERCURIUS™

Targeted DRUG-seq kits

Massively multiplexed and targeted RNA-seq directly on cell, organoid and tissue lysates - no need for prior RNA extraction.

Compatible with Illumina^®and AVITI™ sequencing systems.

Benefits

Custom-developed panels: Users communicate their targets of interest, and we will develop ad-hoc detection panels.

Up to 100 targets: Experimentally validated panels for differential expression analysis.

No RNA extraction needed: An optimized lysis buffer for RNA solubilization.

One-day lab workflow: Convenient and short protocol from samples to sequencing-ready libraries in one day.

MERCURIUS^TM

Targeted DRUG-seq

The production of our Targeted DRUG-seq kits starts with the client providing us with their genes of interest. We then develop a corresponding custom detection panel and validate it directly using their RNA samples.

As part of the Targeted DRUG-seq kit development, clients simply need to deliver 96—or 384-well plates with frozen cells to our service centers (located in Switzerland and the United States).

Once the targeted gene detection panel validation is complete, we will notify the client and ship a pilot batch of Targeted DRUG-seq library prep kits. Upon receiving the client's approval, we will commence production of the custom kit batch.

Optional downstream differential gene expression analysis are also available upon request.

How it works

Step 1

Client communicates the genes of interest

Gene panel submission form for Targeted BRB-seq or Targeted DRUG-seq

Step 2

Client prepares a sample plate for targeted gene panel validation

Sample submission guidelines for MERCURIUS^TM Targeted DRUG-seq service

Step 3

Client ships the frozen sample plate to Alithea

Step 4

Alithea develops and validates the custom detection panel on customer's samples

4 to 8 weeks

Step 5

Client checkpoint - Alithea ships a pilot batch

Step 6

Upon client's approval, Alithea begins the dedicated batch production of custom kits

Product specifications
Validated cell lines

For (application)	Targeted RNA sequencing
For use with (equipment)	Illumina®, AVIT™I and MGI instruments
Species compatibility	All eukaryotic species
Shipping conditions	Dry ice
Storage conditions	-20C

Cell line	Specie	Tissue	Culture type
A375	h.sapiens	Skin, malignant melanoma	adherent
GM12878	h.sapiens	PBMC, lymphoblastoid	suspension
H295R	h.sapiens	Adrenal gland, carcinoma	adherent
HAP1	h.sapiens	KBM-7 derived, chronic myelogenous leukemia	adherent
hASC	h.sapiens	Patient-derived adipose stromal cells	adherent
hASC-Adipocytes	h.sapiens	Differentiated hASC	adherent
HEK293	h.sapiens	Kidney embryonic	adherent
HeLa	h.sapiens	Cervix, adenocarcinoma	adherent
HepG2	h.sapiens	Liver, carcinoma	adherent
Huh7	h.sapiens	Liver, carcinoma	adherent
iNeurons	h.sapiens	Differentiated iPSC	adherent
MCF-7	h.sapiens	Breast, adenocarcinoma	adherent
PANC-1	h.sapiens	Pancreas, carcinoma	adherent
U2OS	h.sapiens	Bone, osteosarcoma	adherent

Product specifications

Validated cell lines

FAQs

Each Targeted DRUG-seq contains reagents (including four pairs of Unique Dual Indexing adapters) sufficient to complete the library preparation process for four different DRUG-seq pools.

To note, the total number of RNA samples that can be processed with one kit does not exceed the kit specifications; for instance, a 96-sample kit can be used to prepare up to 96 samples distributed across up to four different libraries.

Try our service

The MERCURIUS™ Targeted DRUG-seq service offers the most comprehensive, high-throughput and cost-efficient solution for targeted gene expression analysis projects starting from 2D cell cultures.

COmplementary service

Cells and organoids (Extraction-free)

Purified RNA

Accessories

Cells and Organoids (EXTRACTION-FREE)

PURIFIED RNA

Whole Blood RNA